중증근무력증 치료제 시장 예측(-2030년) : 유형별, 약물 유형별, 치료법별, 유통 채널별, 지역별 세계 분석

According to Stratistics MRC, the Global Myasthenia Gravis Treatment Market is accounted for $2.2 billion in 2023 and is expected to reach $3.9 billion by 2030 growing at a CAGR of 8.5% during the forecast period. The Myasthenia Gravis (MG) treatment market refers to the pharmaceutical and therapeutic landscape focused on addressing Myasthenia Gravis, a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue. It encompasses a range of medical interventions aimed at managing symptoms, improving neuromuscular transmission, and enhancing the overall quality of life for individuals with MG.

According to the National Organization for Rare Disorders (NORD), in the U.S., around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders worldwide.

Market Dynamics:

Driver:

Drug approvals and pipeline developments

Treatment for myasthenia gravis (MG) is largely driven by pipeline advancements and drug approvals. New drug approvals provide more therapeutic options, filling gaps in the market and improving patient outcomes. A dedication to improving treatment modalities with potential advancements in drug mechanisms and increased efficacy is indicated by ongoing pipeline developments. Additionally, these developments could result in more individualized and focused treatment plans for MG patients, reducing side effects, and improving management.

Restraint:

Lack of disease-modifying therapies

Concerning the complex and multifactorial nature of autoimmune disorders, there are currently no disease-modifying therapies available for the treatment of myasthenia gravis (MG). Targeted therapy development is difficult because, unlike some other autoimmune diseases, the underlying mechanisms causing MG are not fully understood. The majority of current therapies use acetylcholinesterase inhibitors and immunosuppression to manage symptoms; they relieve symptoms but do not address the underlying cause. However, though there is still much to learn about the exact mechanisms underlying MG and the development of disease-modifying treatments, the disorder's complexity continues to be a major barrier.

Opportunity:

Combination therapies

Combination therapies provide a promising approach to treating myasthenia gravis (MG) by addressing various aspects of the disease. Acetylcholinesterase inhibitors and immunosuppressive medications, such as corticosteroids or immunomodulators, work in concert to manage MG's characteristic muscle weakness and autoimmune response. Additionally, novel biologic therapies that target particular immune pathways have the potential to be combined with conventional medical interventions. Combination therapies seek to maximize effectiveness while reducing side effects related to high dosages of individual medications by addressing different aspects of the intricate pathophysiology.

Threat:

Variability in patient response

Patients with Myasthenia Gravis have a complex autoimmune disorder, and their responses to therapies vary from person to person. Treatment outcomes vary depending on a number of factors, including comorbidities, disease severity, and genetic variations. To address this issue, precision medicine approaches are being investigated with the goal of customizing treatments based on unique patient characteristics. However, pharmaceutical companies and medical professionals continue to be concerned about the inherent variability in MG patient responses, which has an impact on the standardization and optimization of therapeutic interventions available on the market.

COVID-19 Impact:

Significant disruptions in healthcare services and supply chains have affected patient access to medications, making COVID-19 a major factor in the market for Myasthenia Gravis (MG) treatment. While telemedicine has opened up new consultation options, in-person treatments such as plasma exchange or intravenous immunoglobulin (IVIG) have encountered logistical difficulties. Furthermore, the pandemic's financial burden has affected patient affordability and healthcare budgets, which has affected the market for MG therapies. Not with standing these difficulties, ongoing research and development initiatives keep looking into novel MG treatments that address both present roadblocks and potential future market dynamics.

The cholinesterase inhibitors segment is expected to be the largest during the forecast period

The market for myasthenia gravis treatment has witnessed robust growth in the cholinesterase inhibitors segment because of the drug's effectiveness in treating the symptoms of the autoimmune neuromuscular disease. By stopping the breakdown of acetylcholine, cholinesterase inhibitors like pyridostigmine are essential in improving neuromuscular transmission and, consequently, muscle strength and function. Additionally, the market is expected to continue expanding as myasthenia gravis treatments change and more healthcare providers include cholinesterase inhibitors in all-encompassing treatment plans.

The intravenous therapy segment is expected to have the highest CAGR during the forecast period

Given its ability to quickly alleviate acute symptoms of the disease, intravenous therapy (IVT) has become a growing segment in the market for myasthenia gravis treatment. When it comes to treating Myasthenia gravis exacerbations, intravenous administration enables accurate dosage control and prompt delivery of immunosuppressive drugs like intravenous immunoglobulin (IVIG). In severe cases, this mode of therapy is especially helpful as it guarantees a prompt response in stabilizing patients. Furthermore, the convenience of in-home IVT and improvements in infusion technologies support the growth of this market segment by giving patients a more convenient and accessible treatment option, which in turn propels market expansion.

Region with largest share:

Myasthenia Gravis (MG) treatment sales have increased substantially in the Asia-Pacific region as a result of rising MG prevalence, improving healthcare facilities, and growing public awareness of the condition. New treatment options have been introduced as a result of an increase in research and development activities in the region. Government programs to improve healthcare affordability and accessibility have also been essential in promoting market expansion. Furthermore, the treatment landscape for myasthenia gravis is constantly changing, and the APAC region is a major contributor to this evolution with its growing emphasis on personalized medicine and biotechnology advancements.

Region with highest CAGR:

The European market for myasthenia gravis treatment is constantly growing as a result of new treatments being introduced, raising awareness, and improvements in medical research. The expansion of treatment options are facilitated by partnerships between pharmaceutical companies and healthcare organizations. Additionally, the region's growing patient awareness and improved healthcare infrastructure is propelling the market expansion for myasthenia gravis treatment.

Key players in the market:

Some of the key players in Myasthenia Gravis Treatment market include AbbVie Inc., Alexion Pharmaceutical Inc., Amyasthenia gravisen inc., Astellas pharma inc., Astrazeneca, Avadel Pharmaceuticals plc, Bausch Health Companies Inc., Baxter International, Inc., Bayer ag, Biogen, Bristol-myers squibb, CSL Behring, Daiichi sankyo co. Ltd., F. Hoffmann-La Roche Ltd., Gilead sciences inc., Glaxosmithkline plc., Grifols SA, Merck & co. Inc., Novartis AG, Pfizer, Inc., Sanofi, Servier laboratories, Shire plc, Takeda Pharmaceutical Company Limited, Teva pharmaceutical industries ltd. and Valeant Pharmaceuticals International, Inc.

Key Developments:

In December 2023, GSK announced that the European Commission (EC) has granted marketing authorization to its cancer drug, Jemperli (dostarlimab), for expanded use in primary advanced or recurrent endometrial cancer. The EC has now approved Jemperli in combination with carboplatin and paclitaxel as a frontline treatment for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced/recurrent endometrial cancer in adult patients who are candidates for systemic therapy.

In December 2023, Moderna and Merck & Co said they have started a late-stage trial of their experimental personalized mRNA cancer treatment in combination with blockbuster drug Keytruda for patients with a type of lung cancer. The therapy, V940, belongs to a class of treatments called m-RNA-based individualized neoantigen therapy (INT) and is tailored for each patient to generate T-cells, a key part of the body's immune response, based on the specific mutational signature of a tumour.

Drug Classes Covered:

• Cholinesterase Inhibitors
• Monoclonal Antibodies
• Corticosteroids
• Immunosuppressants
• Intravenous Immunoglobulins
• Other Drug Classes

Treatment Modalities Covered:

• Surgery
• Intravenous Therapy
• Other Treatment Modalities

Types Covered:

• Generalized Myasthenia Gravis
• Ocular Myasthenia Gravis
• Transient Neonatal Myasthenia Gravis
• Other Types

Distribution Channels Covered:

• Online Pharmacies
• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channels

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Emerging Markets
• 3.7 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Myasthenia Gravis Disease Treatment Market, By Type

• 5.1 Introduction
• 5.2 Generalized Myasthenia Gravis
• 5.3 Ocular Myasthenia Gravis
• 5.4 Transient Neonatal Myasthenia Gravis
• 5.5 Other Types

6 Global Myasthenia Gravis Disease Treatment Market, By Drug Class

• 6.1 Introduction
• 6.2 Cholinesterase Inhibitors
• 6.3 Monoclonal Antibodies
• 6.4 Corticosteroids
• 6.5 Immunosuppressants
• 6.6 Intravenous Immunoglobulins
• 6.7 Other Drug Classes

7 Global Myasthenia Gravis Disease Treatment Market, By Treatment Modality

• 7.1 Introduction
• 7.2 Surgery
• 7.3 Intravenous Therapy
• 7.4 Other Treatment Modalities

8 Global Myasthenia Gravis Disease Treatment Market, By Distribution Channel

• 8.1 Introduction
• 8.2 Online Pharmacies
• 8.3 Hospital Pharmacies
• 8.4 Retail Pharmacies
• 8.5 Other Distribution Channels

9 Global Myasthenia Gravis Disease Treatment Market, By Geography

• 9.1 Introduction
• 9.2 North America
  • 9.2.1 US
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 Italy
  • 9.3.4 France
  • 9.3.5 Spain
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 New Zealand
  • 9.4.6 South Korea
  • 9.4.7 Rest of Asia Pacific
• 9.5 South America
  • 9.5.1 Argentina
  • 9.5.2 Brazil
  • 9.5.3 Chile
  • 9.5.4 Rest of South America
• 9.6 Middle East & Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 UAE
  • 9.6.3 Qatar
  • 9.6.4 South Africa
  • 9.6.5 Rest of Middle East & Africa

10 Key Developments

• 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 10.2 Acquisitions & Mergers
• 10.3 New Drug Class Launch
• 10.4 Expansions
• 10.5 Other Key Strategies

11 Company Profiling

• 11.1 AbbVie Inc.
• 11.2 Alexion Pharmaceutical Inc.
• 11.3 Amyasthenia gravisen inc.
• 11.4 Astellas pharma inc.
• 11.5 Astrazeneca
• 11.6 Avadel Pharmaceuticals plc
• 11.7 Bausch Health Companies Inc.
• 11.8 Baxter International, Inc.
• 11.9 Bayer ag
• 11.10 Biogen
• 11.11 Bristol-myers squibb
• 11.12 CSL Behring
• 11.13 Daiichi sankyo co. Ltd.
• 11.14 F. Hoffmann-La Roche Ltd.
• 11.15 Gilead sciences inc.
• 11.16 Glaxosmithkline plc.
• 11.17 Grifols SA
• 11.18 Merck & co. Inc.
• 11.19 Novartis AG
• 11.20 Pfizer, Inc.
• 11.21 Sanofi
• 11.22 Servier laboratories
• 11.23 Shire plc
• 11.24 Takeda Pharmaceutical Company Limited
• 11.25 Teva pharmaceutical industries ltd.
• 11.26 Valeant Pharmaceuticals International, Inc.